Patrick G. Enright - 09 Oct 2025 Form 4 Insider Report for Zenas BioPharma, Inc. (ZBIO)

Reporting relationship: Director
Issuer ticker: ZBIO
Reported as of: 09 Oct 2025
Net transaction value: +$2,250,026
SEC form: 4
Accepted by SEC: 14 Oct 2025, 08:59:40 UTC
Prior SEC filing: 08 Jan 2026
Next SEC filing: 15 Dec 2025
Source filing: View source filing
Reporting owner signature: By: /s/ Cristiana Oliveira, attorney-in-fact for Patrick G. Enright

Key filing fact

Patrick G. Enright filed Form 4 for Zenas BioPharma, Inc. (ZBIO) on 14 Oct 2025.

Key facts

This page summarizes Patrick G. Enright's Form 4 filing for Zenas BioPharma, Inc. (ZBIO).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 14 Oct 2025, 08:59.

Change

Previous filing in this sequence was filed on 08 Jan 2026.
Current net transaction value: +$2,250,026.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001253886 Primary reporting owner

ENRIGHT PATRICK G

Relationship: Director
Address: C/O ZENAS BIOPHARMA, INC., 1000 WINTER STREET, SUITE 1200, WALTHAM
Signature: By: /s/ Cristiana Oliveira, attorney-in-fact for Patrick G. Enright
Signature date: 14 Oct 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ZBIO transaction

Common Stock

Purchase

Transaction value: $2,000,035
Shares: +105,265
Change %: +6.1%
Price: $19.00
Shares after: 1,832,669
Date: 09 Oct 2025
Ownership: See Footnote
Footnotes: F1, F2

ZBIO transaction

Common Stock

Purchase

Transaction value: $249,992
Shares: +11,990
Change %
Price: $20.85
Shares after: 11,990
Date: 09 Oct 2025
Ownership: Direct
Footnotes: F1

ZBIO holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 774,530
Date: 09 Oct 2025
Ownership: See Footnote
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

On October 7, 2025, the Issuer entered into a Securities Purchase Agreement with certain investors, including the Reporting Person and Longitude Venture Partners IV, L.P. ("LVPIV") pursuant to which the Reporting Person purchased 11,990 shares of common stock at a price per share of $20.85 and LVPIV purchased 105,265 shares of common stock as a price per share of $19.00 (the "Offering"). The Offering closed on October 9, 2025.

Footnote F2

Shares held by LVPIV. Longitude Capital Partners IV, LLC ("LCPIV") is the general partner of LVPIV and may be deemed to have voting, investment and dispositive power with respect to these securities. Juliet Tammenoms Bakker and the Reporting Person, a member of the board of directors of the Issuer, are the managing members of LCPIV and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of LCPIV, Ms. Bakker and the Reporting Person disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interests therein.

Footnote F3

Shares held by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP") is the general partner of LPF and may be deemed to have voting, investment and dispositive power with respect to the securities held by LPF. Juliet Tammenoms Bakker and the Reporting Person, a member of the board of directors of the Issuer, are the managing members of LPP and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of LPP, Ms. Bakker and the Reporting Person disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interests therein.